Biovica International (STO:BIOVIC-B; STO:BIOVIC.B; FRA:911) has announced the signing of a significant work order for TKa testing services, valued at 2.3 MSEK. The agreement has been made with a UK-based pharmaceutical/biotech company for use in a Phase I/II clinical study involving patients with advanced solid tumors treated with a next-generation CDK inhibitor.
According to Biovica, the order builds on the success of a smaller proof-of-concept study that yielded promising results, paving the way for the larger clinical study work order.
“We are pleased to see the strong development in our Pharma Services business. TKa is now used in 15 ongoing trials, increasing the likelihood of TKa being validated as a companion biomarker for patient treatment monitoring and optimization. Another MSA customer, who is also developing next-generation CKD inhibitors in Phase I/II, just signed its eighth work order with us. Large and repeat business makes me confident about the future,” said Henrik Winther, SVP, business development at Biovica.
